OPEN ACCESS

Development of endometrial cancer after long-term usage of the levonorgestrel-releasing intrauterine system

Alexander Steshenko ,¹ Leila Hanna,¹ Damian Collins²

¹Obstetrics and Gynaecology, Queen Elizabeth Hospital, London, UK

²Pathology, Queen Elizabeth Hospital, London, UK

Correspondence to
Dr Alexander Steshenko;
asteshenko@nhs.net

Accepted 11 April 2021

SUMMARY

A 52-year-old long-term user of the levonorgestrel-releasing intrauterine system (LNG-IUS) presented with vaginal bleeding. Endometrial biopsy was performed and revealed endometrioid adenocarcinoma. The patient had a laparoscopic hysterectomy and bilateral salpingo-oophorectomy. Endometrial cancer is rare in women with LNG-IUS as only seven cases have been published in the literature. Although scientific evidence shows LNG-IUS has a protective effect on the endometrium from developing cancer, our report highlights the importance of clinicians to be vigilant in cases of women with LNG-IUS who develop intermittent vaginal bleeding.

BACKGROUND

Endometrioid endometrial adenocarcinoma is rare in women using levonorgestrel-releasing intrauterine system (LNG-IUS). Therefore, when a patient with long-term usage of LNG-IUS for menorrhagia presents with intermittent vaginal bleeding, the level of suspicion for endometrial cancer usually can be very low, which may lead to a significant delay in further investigation, diagnosis and, as a result may delay in treatment that can be potentially life-saving.

Herein, we present a rare case of a patient with LNG-IUS who was diagnosed with endometrial cancer.

CASE PRESENTATION

A female patient presented to a gynaecology clinic when she was 37 years of age, complaining of regular heavy menstrual bleeding. She had no medical conditions, such as obesity, diabetes or hypertension. In the past, she had two uncomplicated pregnancies, and both were spontaneous vaginal delivery at term. Her grandmother in her 50th and aunt at age of 70 years both on maternal side had uterine cancer. She had 3 yearly cervical cytology testing which was uneventful. Speculum and bimanual vaginal examination demonstrated no abnormalities of cervix, uterus and adnexa. The transvaginal scan was also unremarkable. Endometrial biopsy was not required at this stage as it was not part of routine investigation for menorrhagia. After counselling about menorrhagia treatment options, the patient chose to have IUS containing 52 mg levonorgestrel released at a rate of 20 µg/24 hours, which was inserted into the uterine cavity.

Six months later, the patient informed her gynaecologist that periods became lighter, and

she was satisfied with the effect of LNG-IUS. The patient used the same type of LNG-IUS, which was replaced two times at the exact 5 yearly intervals in our hospital, and it was documented in her medical records. Her body mass index remained normal, and she had no medical conditions.

At 51 years of age, the patient developed intermittent vaginal bleeding with a backache. The patient saw her general practitioner (GP) because of irregular vaginal bleeds; the GP requested a serum Follicle-stimulating hormone (FSH) level and a transvaginal ultrasound scan. The FSH was 37.3 U/L. The transvaginal ultrasound scan showed an endometrial thickness of 8.3 mm; both ovaries had normal morphology and clear outline measuring 24 mm × 21 mm × 21 mm and 25 mm × 18 mm × 22 mm. Given the persistence of vaginal bleeding, the GP referred her to the gynaecology clinic for review and further management.

When the patient was reviewed in gynaecology outpatient clinic, the intermittent vaginal bleeding continued to be the main presenting complaint. On examination, there was a mild cystocele, hypertrophic cervix and a bulky anteverted uterus. The gynaecologist reviewing the patient assumed that menorrhagia symptoms were returning because of an expiring LNG-IUS even though the patient's next IUS replacement was due only in 12 months. At this point, it was 14 years from the date when the patient started LNG-IUS treatment for menorrhagia. Since the patient had intermittent bleeding, the gynaecologist took an endometrial biopsy and replaced the LNG-IUS.

INVESTIGATIONS

The endometrial biopsy showed complex endometrial hyperplasia with grade 1 endometrioid adenocarcinoma (figure 1).

The patient had CT (chest, abdomen, pelvis) and MRI (pelvis and abdomen) scans as part of the local protocol to investigate patients with all types of endometrial cancer. Both scans were suspicious for endometrial malignancy with <50% of myometrial invasion and no evidence of local or distant metastasis.

DIFFERENTIAL DIAGNOSIS

Treatment of menorrhagia was the main reason for the patient to use LNG-IUS for 14 years before being diagnosed with endometrial cancer. When irregular bleeding symptoms started and persisted, the cause for the bleeding was thought to be probable

© BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Steshenko A, Hanna L, Collins D. *BMJ Case Rep* 2021;**14**:e242094. doi:10.1136/bcr-2021-242094

Figure 1 A low-power H&E view of the original endometrial biopsy showing a mixture of endometrioid carcinoma and benign changes related to exogenous hormone administration (levonorgestrel-releasing intrauterine system in this instance).

expulsion of the LNG-IUS. However, a speculum examination and transvaginal ultrasound scan confirmed the intrauterine position of the LNG-IUS.

Another suggestion was that vaginal bleeding was due to an expiring IUS, which might produce insufficient levonorgestrel levels and fail to achieve amenorrhoea which some women could experience after the IUS insertion. This suggestion was supported by the ultrasound scan showing the endometrial thickness of 8.4 mm and indicating the endometrium could be still active. Suspicion for endometrial hyperplasia and endometrial cancer, in this case, was low because prolonged and continuous use of the LNG-IUS can prevent these conditions, and in some cases could even be used for their treatment. The menopausal status was also unclear due to previously diminished periods secondary to the LNG-IUS, which added some confusion to the differential diagnosis of the vaginal bleeding. The persistence of the symptoms and the patient's age prompted to manage the patient as one with suspected endometrial malignancy. The endometrial biopsy was taken showing complex endometrial hyperplasia with endometrioid adenocarcinoma.

TREATMENT

The case was initially discussed at a multidisciplinary team (MDT) meeting at the local district general hospital (DGH), then at an MDT meeting with specialists in oncology gynaecology, histopathology, radiology at a leading regional cancer centre in London (UK). Based on the medical, radiological and histological information, the MDT members consensus at both sites was that the patient had a grade 1 endometrioid adenocarcinoma of the endometrium, probable tumour, node, metastases stage pT1a, The International Federation of Gynaecology and Obstetrics (FIGO) stage IA.

The MDT members at the specialist meeting recommended a total laparoscopic hysterectomy and bilateral salpingo-oophorectomy without lymph node dissection (LND). The advice was based on studies conducted by Janda *et al* and Walker *et al*¹²: in women with stage 1 endometrial cancer, total laparoscopic hysterectomy compared with total abdominal hysterectomy resulted in similar disease-free and overall survival rates.

Figure 2 A juxtaposition between the endometrioid adenocarcinoma on the right and the predecidual stroma induced by levonorgestrel-releasing intrauterine system on the left.

The specialist MDT meeting recommended not to perform LND because patients with a low-risk type of cancer such as endometrioid type and <50% myometrial invasion had a very low probability of lymphadenopathy.³ Moreover, evidence from two randomised controlled trials conducted by Benedetti Panici *et al*, and Kitchener *et al* demonstrated that systematic pelvic lymphadenectomy in women with clinical stage 1, low-risk endometrial cancer had no added benefits in improving disease-free and overall survival rates.^{4,5} Such management strategy was also supported by guidance from the latest ESMO-ESGO-ESTRO (European Society for Medical Oncology- European Society of Gynaecological Oncology- European Society for Radiotherapy and Oncology) consensus on endometrial cancer.⁶

In accordance with the endometrial cancer surgery policy for South-East London, grade 1 tumours are operated on at the local DGH treating the patient; therefore, the patient had a total laparoscopic hysterectomy and bilateral salpingo-oophorectomy carried out at the DGH, with no complications. She was discharged home the following day after surgery.

OUTCOME AND FOLLOW-UP

The reporting pathologist at the DGH provided the descriptions of the specimen. Microscopically, the sections taken from the uterus showed an endometrioid adenocarcinoma of the endometrium involving the inner half of myometrium (figures 2–7). The background endometrium had cystic atrophy and effect of progestogen administration. The histopathologist concluded it was endometrioid carcinoma pT1a FIGO grade 1A with no or <50% myometrial invasion, a 10 mm tumour-free distance to serosa, no lymphovascular invasion and no evidence of microscopic involvement of cervical stroma.

The patient fully recovered after surgery and she was seen in the gynaecology outpatient clinic 4 months after the procedure as part of routine postoperative follow-up. After discussing with the patient, we agreed that we would follow her up on annual basis, focusing on the screening for asymptomatic pelvic or vaginal vault recurrence provided. One-year follow-up with pelvic MRI scan, vaginal vault cytology and examination, which is the standard practice in our hospital, showed no evidence of recurrence.

Figure 3 The same field as in figure 2 and with the oestrogen receptor stain, which shows strong nuclear staining of the tumour cells (strongly positive).

Given the patient family history of uterine cancer, the endometrial cancer was tested for mismatch repair (MMR) deficiency. The test showed patchy weak nuclear staining for mutL homologue 1 (MLH-1), postmeiotic segregation increased 2 (PMS-2) and mutS homologue 2 (MSH-2) with variable staining of background internal control. Although it was difficult to interpret, this was likely represented intact expression. Testing for MSH-6 showed complete loss of nuclear staining in the tumour area with preserved background internal control, which was interpreted as MSH-6-deficient tumour. In view of MMR result we referred the patient to our local research cancer centre to be tested for possible Lynch syndrome, which is an inherited mutation genes disorder associated with endometrial cancer. The result of the testing for Lynch syndrome was unavailable during writing the report.

DISCUSSION

The LNG-IUS is used in gynaecological practice for contraception, treatment of menorrhagia and endometrial hyperplasia. The most common type of IUS used usually contains 52 mg of levonorgestrel delivered with a rate of 20 mcg/24 hours.⁷ LNG's

Figure 4 The same field as in figure 2 showing similar strong expression of the progesterone receptor.

Figure 5 The tumour invading the inner half of the myometrium (stage pT1a).

effect to suppress endometrial proliferation is used in women receiving hormone replacement therapy and, in patients treated with tamoxifen to prevent recurrence of breast cancer.⁸ There were also case reports where the LNG-IUS was used to treat women with early stages of endometrial cancer who wished to preserve their fertility.⁹

The effect of the LNG-IUS on endometrium and uterus was extensively studied and found that continuous release of LNG into the uterine cavity causes significant changes in endometrial morphology and function. Common histological changes reported by Phillips *et al* were decidualisation of stroma (96%), atrophy of glands (87%), stromal inflammatory cell infiltrate with and without plasma cells (79% and 27%) and surface papillary formations (51%).¹⁰ Furthermore, morphological features associated with LNG-IUS use were stromal myxoid change (39%) and stromal haemosiderin deposition (32%). Glandular metaplasia (9%), stromal necrosis (7%), reactive atypia in surface glands (4%) and stromal calcifications (1%) were also observed but were less common.¹⁰

Development of endometrial cancer in long-term LNG-IUS users is very rare. Only seven cases were reported in the literature to date (table 1).^{11–16} Our patient is unique due to

Figure 6 An overview of the solid nature of the tumour filling part of the endometrial cavity.

Figure 7 A contrast between the tumour and the uninvolved flat endometrium on the other side of the endometrial cavity.

continuous LNG-IUS use (14 years) before she was diagnosed with endometrial cancer. Previously reported cases showed that the longest period LNG-IUS was used before the development of endometrial cancer was 4 years. The majority of women in case reports, including our case, were perimenopausal or postmenopausal (between 48 and 55 years old). Only two out of seven women were premenopausal (36 and 38 years of age). Most patients (four out of six) were multiparous, one was nulliparous, and in one case there was no information about parity. Analysis of case reports showed that the most common reason for LNG-IUS insertion was treating previously diagnosed menorrhagia. Interestingly, in all cases, reported patients had the same type of IUS, which contained 52 mg levonorgestrel-releasing 20 mcg of the hormone every 24 hours. This coincident could be because only one brand of LNG-IUS was available on the market to treat menorrhagia at that time.

In all seven patients with LNG-IUS reported in the literature who were diagnosed with endometrial cancer, the main

presenting symptoms were prolonged or irregular vaginal bleeding. Although case reports stated that patients developed endometrial cancer after starting treatment with the LNG-IUS, the data should be interpreted with caution because only two patients had an endometrial biopsy before insertion of the LNG-IUS. In both cases, endometrial biopsies were reported as benign non-secretory or proliferative endometrium.

All patients had endometrioid endometrial adenocarcinoma. It is subtype I, hormone-receptor-positive, low-grade, diploid endometrial cancer with a generally good prognosis.¹⁷ A literature search failed to identify cases where patients with the LNG-IUS develop subtype II non-endometrioid cancer, described as hormone receptor negative, high-grade, and aneuploid. Subtype II cancer generally has a poor prognosis and a higher risk of metastasis.

Our case is also unique because the patient had no recognised risk factors for endometrial cancer, including exposure to endogenous and exogenous oestrogen levels, diabetes, obesity, early age at menarche, nulliparity, late menopause and use of tamoxifen.¹⁸ However, it is essential to remember that our patient had no endometrial biopsy before the insertion of the LNG-IUS.

The pathogenetic mechanism in the development of endometrial cancer in the presence of LNG-IUS is unknown. However, the most plausible mechanism could be that women might initially develop endometrial hyperplasia, causing excessive menstrual bleeding, then hyperplasia gradually progresses to endometrioid endometrial adenocarcinoma, even in the presence of the LNG-IUS. The latest evidence of molecular profiling can support this theory. Some endometrial cancers can be caused by microsatellite instability, which is the result of non-functioning of the DNA MMR system, described as a high frequency of frameshift mutations in microsatellite DNA.¹⁹ An example of this could be germline mutations in either of the MMR genes such as *MLH-1*, *MSH-2*, *MSH-6* and *PMS-2*, leading to Lynch syndrome which is present in up to 2%–5% of patients with uterine cancer.²⁰ Lynch syndrome is inherited by autosomal dominant mutation-promoting colon, endometrial and ovarian tumours. Similarly, mutations of *PTEN*, *PIK3CA*, *KRAS*, *BRAF* and *POLE* genes also can be associated with endometrial cancer,^{20 21} which could be an

Table 1 Reported in literature cases of endometrial cancer in patients with LNG-IUS

Author	Age of patient, years	Duration of LNG-IUS used	Diagnosis	Endometrial biopsy before LNG-IUS use	Body mass index, kg/m ²	Parity	Presenting symptoms
Kuzel <i>et al</i> ¹¹	52	46 months	Polyp endometrioid adenocarcinoma Grade 1 Stage1	No	26.7	Multiparous	Routine check-up USS: polyp 12×5 mm
Thomas and Briggs ¹²	50	Unknown	Endometrioid carcinoma Grade 1 Stage 1A	No		Unknown	Persistent vaginal bleeding
Abu <i>et al</i> 2006 ¹³	36	5 months	Endometrioid adenocarcinoma Grade 2 Stage 1B	No		Unknown	Irregular vaginal bleeding
Flemming <i>et al</i> ¹⁴	39	4 years	Endometrioid adenocarcinoma Grade 2 Stage 1B	Benign non-secretory endometrium	39.5	Multiparous	Vaginal bleeding for 8 months
Ndumbe and Husemeyer 2006 ¹⁵	55	4 years	Endometrioid adenocarcinoma Grade 2 Stage 1C	No		Multiparous	Intermittent vaginal bleeding
Jones <i>et al</i> ¹⁶	54 48	1 year 3 years	Endometrial carcinoma Grade1 Stage 2B Endometrial adenocarcinoma Grade 2 Stage 3C	Proliferative endometrium No		Multiparous Nulliparous	Irregular heavy vaginal bleeding

LNG-IUS, levonorgestrel-releasing intrauterine system; USS, ultrasound scan.

aetiological factor in the pathogenic mechanism of endometrioid adenocarcinoma in women using the LNG-IUS.

Although LNG-IUS can cause changes to the endometrium as described earlier, most evidence indicates that long-term use of the LNG-IUS is rather protective of malignancies. For instance, the LNG-IUS significantly decreases endometrial proliferation by promoting apoptosis of endometrial glands and stroma.²² The underlying molecular mechanism by which LNG-IUS causes atrophic change in endometrium can be associated with increased Fas antigen expression and decreased Bcl-2 protein expression. The Fas antigen is a mediator of apoptotic signal in the Fas/Fas ligand system responsible for early apoptosis, whereas Bcl-2 protein promotes survival of cells in the endometrium.^{23 24} The LNG-IUS can also suppress angiogenesis in endometrium by decreasing expression of vascular endothelial growth factor, which is required for rapid endothelial proliferation and spiral arterioles coiling.²⁵

Further evidence indicating LNG-IUS protective properties against endometrial cancer and other malignancies was a large retrospective cohort study that compared rates of various cancers between users and non-users of the LNG-IUS for treatment of menorrhagia.²⁶ The LNG-IUS users had a lower standardised incidence ratio of endometrial adenocarcinoma which was 0.50 (95% CI: 0.35 to 0.70) after the IUS was used the first time and 0.25 (95% CI: 0.05 to 0.73) after its use was extended for a second time. Also, there was a reduction in the incidence of pancreatic cancer (95% CI: 0.28 to 0.81), ovarian cancer (95% CI: 0.45 to 0.76) and lung cancer (95% CI: 0.49 to 0.91). However, breast cancer's standardised incidence ratio was higher than expected in LNG-IUS users (95% CI: 1.13 to 1.25). The authors concluded that the LNG-IUS has a protective effect against endometrial transformation leading to malignancy.

The standard practice to diagnose an endometrial cancer is endometrial biopsy. MRI scan is a first-line image method used for assessment and staging of endometrial cancer. MRI is chosen over CT scan based on the systematic review of 18 studies conducted by Selman *et al*, which found that MRI and sentinel node biopsy were the most accurate tests in assessing lymph nodes' status in women with endometrial cancer.²⁷ Also, MRI is superior to CT scan in terms of radiation risk.

Treatment for FIGO stage I with grade 1 endometrioid adenocarcinoma is a surgery which can be limited to hysterectomy and bilateral salpingo-oophorectomy.²⁸ However, in some cases further surgery or adjuvant treatment may be required, if histological grade on preoperative biopsy was underestimated.

In the UK, the traditional follow-up of gynaecological cancer has a similar pathway: clinical examination in secondary care outpatient clinics every 3 months for the first 3 years and annually for further 2 years. Because of a shortage of robust evidence concerning follow-up in women after surgery for endometrioid endometrial adenocarcinoma, the British Gynaecological Cancer Society (BGCS) published guideline on the management of endometrial cancer, including advice on follow-up strategy.²⁸ BGCS recommended adopting individualised follow-up with the package of care designed to screen for recurrence, side effects and consequences of treatment received, patients' choices. For instance, women with low risk of recurrence, which includes stage 1 of endometrioid endometrial adenocarcinoma, can have a limited number of infrequent visits within the first 2 years or can be discharged to patient-initiated follow-up.

In conclusion, endometrioid endometrial adenocarcinoma is very rare in patients using the LNG-IUS to treat menorrhagia. In these cases, the aetiology of cancer could be due to mutation in MMR gene MSH-6 or undiagnosed endometrial hyperplasia. It

Patient's perspective

I felt that my diagnosis was delayed mainly at the stage of primary care where my vaginal bleeding was not taken seriously. Also, it was a delay between the start of the bleeding and my referral to the hospital. Since I never had an endometrial biopsy before and during treatment with Mirena coil for vaginal bleeding I felt frustration from unknowing if I had a pre-cancer condition in my uterus in the past and continuous use of Mirena prevented it progression to the cancer or if it was that using the coil in itself caused the change which led to development of the cancer.

Learning points

- Patients with irregular vaginal bleeding should have endometrial biopsy.
- Endometrial cancer is very rare in patients with LNG-IUS.
- A mismatch repair profile should be considered to exclude inherited mutation gene disorders.

is also possible that if the patient had endometrial hyperplasia, the LNG-IUS continuous use could have delayed its progression to cancer.

Contributors AS performed literature review and wrote the article. LH contributed to the intellectual content and edited the article. DC contributed to editing the article and selecting histology photomicrographs for it.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Alexander Steshenko <http://orcid.org/0000-0003-0734-6234>

REFERENCES

- 1 Janda M, GebSKI V, Davies LC, *et al*. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. *JAMA* 2017;317:1224–33.
- 2 Walker JL, Piedmonte MR, Spirtos NM, *et al*. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: gynecologic Oncology Group LAP2 study. *J Clin Oncol* 2012;30:695–700.
- 3 Vargas R, Rauh-Hain JA, Clemmer J, *et al*. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. *Gynecol Oncol* 2014;133:216–20.
- 4 Benedetti Panici P, Basile S, Maneschi F, *et al*. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. *J Natl Cancer Inst* 2008;100:1707–16.
- 5 Kitchener H, Swart AMC, *et al*, ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. *Lancet* 2009;373:125–36.
- 6 Colombo N, Creutzberg C, Amant F, *et al*. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. The ESMO-ESGO-ESTRO endometrial consensus conference Working group. *Annals of Oncology* 2006;27:16–41.
- 7 Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. *Ann Med* 1990;22:85–90.

- 8 Dominick S, Hickey M, Chin J, *et al.* Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. *Cochrane Database Syst Rev* 2015;CD007245.
- 9 Dhar KK, NeedhiRajan T, Koslowski M, *et al.* Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? report of four cases and review of the literature. *Gynecol Oncol* 2005;97:924–7.
- 10 Phillips V, Graham CT, Manek S, *et al.* The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. *J Clin Pathol* 2003;56:305–7.
- 11 Kuzel D, Mara M, Zizka Z, *et al.* Malignant endometrial polyp in woman with the levonorgestrel intrauterine system - a case report. *Gynecol Endocrinol* 2019;35:112–4.
- 12 Thomas M, Briggs P. A case of endometrial carcinoma in a long-term Levonorgestrel Intrauterine System (LNG 52 mg-IUS) user. *Post Reprod Health* 2017;23:13–14.
- 13 Abu J, Brown L, Ireland D. Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman. *Int J Gynecol Cancer* 2006;16:1445–7.
- 14 Flemming R, Sathiyathasan S, Jackson A. Endometrioid adenocarcinoma after insertion of a levonorgestrel-releasing intrauterine system. *J Minim Invasive Gynecol* 2008;15:771–3.
- 15 Ndumbe FM, Husemeyer RP. Endometrial adenocarcinoma in association with a levonorgestrel-releasing intrauterine system (Mirena). *J Fam Plann Reprod Health Care* 2006;32:113–4.
- 16 Jones K, Georgiou M, Hyatt D, *et al.* Endometrial adenocarcinoma following the insertion of a Mirena IUCD. *Gynecol Oncol* 2002;87:216–8.
- 17 Morice P, Leary A, Creutzberg C, *et al.* Endometrial cancer. *Lancet* 2016;387:1094–108.
- 18 Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. *Cancer Epidemiol Biomarkers Prev* 2002;11:1531–43.
- 19 Society of Gynecologic Oncology (SGO). *Sog clinical practice statement: screening for Lynch syndrome in endometrial cancer*. Chicago, IL: Society of Gynecologic Oncology, 2014. sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer. (Accessed January 22, 2021).
- 20 , Kandoth C, Schultz N, *et al.* Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013;497:67–73.
- 21 El-Deiry WS, Goldberg RM, Lenz H-J, *et al.* The current state of molecular testing in the treatment of patients with solid tumors, 2019. *CA Cancer J Clin* 2019;69:305–43.
- 22 Maruo T, Laoag-Fernandez JB, Pakarinen P, *et al.* Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. *Hum Reprod* 2001;16:2103–8.
- 23 Otsuki Y, Misaki O, Sugimoto O, *et al.* Cyclic Bcl-2 gene expression in human uterine endometrium during menstrual cycle. *Lancet* 1994;344:27–9.
- 24 Yamashita H, Otsuki Y, Matsumoto K, *et al.* Fas ligand, Fas antigen and Bcl-2 expression in human endometrium during the menstrual cycle. *Mol Hum Reprod* 1999;5:358–64.
- 25 Laoag-Fernandez JB, Maruo T, Pakarinen P, *et al.* Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis. *Hum Reprod* 2003;18:694–9.
- 26 Soini T, Hurskainen R, Grénman S, *et al.* Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. *Obstet Gynecol* 2014;124:292–9.
- 27 Selman TJ, Mann CH, Zamora J, *et al.* A systematic review of tests for lymph node status in primary endometrial cancer. *BMC Womens Health* 2008;8:8.
- 28 Sundar S, Balega J, Crosbie E, *et al.* BGCS uterine cancer guidelines: recommendations for practice. *Eur J Obstet Gynecol Reprod Biol* 2017;213:71–97.

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <https://www.bmj.com/company/products-services/rights-and-licensing/permissions/>
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow